검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | AIN 457 |
Overview Company | Novartis Pharmaceuticals |
Overview Modality | ANTIBODY |
Overview Target | Non-infectious Uveitis |
Overview Indication | Non-infectious Uveitis |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | targets of the IL-23 pathway |
MoA Biomarker | biomarkers (e |
PK/PD Species | Rat, Human |
PK/PD Animal (cat.) | Human, Rat |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Rat, Human |
Toxicology Animal (cat.) | Human, Rat |
Toxicology Major finding | Secukinumab (AIN-457) for the treatment of Psoriasis.. Secukinumab (also known as AIN-457) is a human monoclonal antibody targeting IL-17A, which has been recently FDA-approved for the treatment of moderate to severe psoriasis and psoriatic arthritis with coexistent moderate to severe plaque psoriasis based on clinical trials demonstrating excellent efficacy. This review will address the rationale… |
Clinical Primary efficacy | ORR 0.5% |
Clinical ORR | 0.5% |
Clinical Result source | ClinicalTrials.gov NCT01250171 |
Clinical Data Tier / Score | A · 31 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | AIN 457 |
Overview Company | Novartis Pharmaceuticals |
Overview Modality | ANTIBODY |
Overview Target | Non-infectious Uveitis |
Overview Indication | Non-infectious Uveitis |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | targets of the IL-23 pathway |
MoA Biomarker | biomarkers (e |
PK/PD Species | Rat, Human |
PK/PD Animal (cat.) | Human, Rat |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Rat, Human |
Toxicology Animal (cat.) | Human, Rat |
Toxicology Major finding | Secukinumab (AIN-457) for the treatment of Psoriasis.. Secukinumab (also known as AIN-457) is a human monoclonal antibody targeting IL-17A, which has been recently FDA-approved for the treatment of moderate to severe psoriasis and psoriatic arthritis with coexistent moderate to severe plaque psoriasis based on clinical trials demonstrating excellent efficacy. This review will address the rationale… |
Clinical Primary efficacy | ORR 0.5% |
Clinical ORR | 0.5% |
Clinical Result source | ClinicalTrials.gov NCT01250171 |
Clinical Data Tier / Score | A · 31 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
추천 비교
추천 비교